継続的なニトログリセリン療法中に血小板の持続的阻害は,血動力学的耐性にもかかわらず
1Department of Medicine, Montreal Heart Institute, University of Montreal Medical School, Canada.
Circulation
|March 4, 1997
まとめ
継続的なニトログリセリン治療は,血動力学的な耐性が発達しても,血小板の堆積と集積を一貫して減少させます. これは,持続的な抗血小板効果が心血管の健康に不可欠であることを示している.
科学分野:
- 心血管薬理学について
- ヘモダイナミクスは,
- 血小板生物学 血小板生物学について
背景:
- ニトログリセリンは,動物とヒトの両方の研究で抗血小板特性を示しています.
- ニトログリセリンの血動力学的効果に対する耐性は,継続的な治療で発生することが知られている.
- 継続的な治療中にニトログリセリンの抗血小板効果が持続するかどうかは不明である.
研究 の 目的:
- 継続的なニトログリセリン療法による抗血小板効果に対する耐性が発達するかどうかを調査する.
- 持続的なニトログリセリンの投与が血小板の機能と蓄積に与える影響を評価する.
主な方法:
- 豚の大動脈介質は,対照豚と連続したニトログリセリンパッチ (0.8 mg/h) を受けた豚からの動脈血液にさらされました.
- 大動脈介質の血小板収納は,高シール条件下で,自律的な51Crラベル付血小板を使用して測定されました.
- トロンビンによって誘発される血小板の集積と血小板内循環グアナシンモノフォスファート (cGMP) レベルが評価されました.
主要な成果:
- 継続的なニトログリセリンの治療は,ベースラインと比較して3,24および48時間で大動脈媒介の血小板収縮を著しく減少させた.
- トロンビン誘発の血小板凝集は,48時間の治療期間中,著しく減少しました.
- ニトログリセリンの投与により,血小板内cGMP濃度が上昇し,持続的な薬理学的作用を示した.
結論:
- 継続的なニトログリセリン治療は,血動力学的効果に対する耐性の発達にもかかわらず,抗血小板効果を維持します.
- この研究は,持続的なニトログリセリンの使用で,血小板機能の持続的な阻害と損傷した動脈壁の堆積を示しています.
- これらの発見は,心血管疾患の管理におけるニトログリセリンの抗血小板作用の重要性を強調しています.
関連する概念動画
01:28Nitric Oxide Signaling Pathway
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:16Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:27Angina II: Classification
Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...